1
|
Armoiry X, Kan A, Melendez-Torres GJ, Court R, Sutcliffe P, Auguste P, Madan J, Counsell C, Clarke A. Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis. J Neurol 2018; 265:999-1009. [PMID: 29356977 PMCID: PMC5937891 DOI: 10.1007/s00415-018-8752-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Revised: 01/11/2018] [Accepted: 01/12/2018] [Indexed: 12/20/2022]
Abstract
Background Beta-interferon (IFN-β) and glatiramer acetate (GA) have been evaluated in people with clinically isolated syndrome (CIS) with the aim to delay a second clinical attack and a diagnosis of clinically definite multiple sclerosis (CDMS). We systematically reviewed trials evaluating the short- and long-term clinical effectiveness of these drugs in CIS. Methods We searched multiple electronic databases. We selected randomised controlled studies (RCTs) conducted in CIS patients and where the interventions were IFN-β and GA. Main outcomes were time to CDMS, and discontinuation due to adverse events (AE). We compared interventions using random-effect network meta-analyses (NMA). We also reported outcomes from long-term open-label extension (OLE) studies. Results We identified five primary studies. Four had open-label extensions following double-blind periods comparing outcomes between early vs delayed DMT. Short-term clinical results (double-blind period) showed that all drugs delayed CDMS compared to placebo. Indirect comparisons did not suggest superiority of any one active drug over another. We could not undertake a NMA for discontinuation due to AE. Long-term clinical results (OLE studies) showed that the risk of developing CDMS was consistently reduced across studies after early DMT treatment compared to delayed DMT (HR = 0.64, 95% CI 0.55, 0.74). No data supported the benefit of DMTs in reducing the time to, and magnitude of, disability progression. Conclusions Meta-analyses confirmed that IFN-β and GA delay time to CDMS compared to placebo. In the absence of evidence that early DMTs can reduce disability progression, future research is needed to better identify patients most likely to benefit from long-term DMTs. Electronic supplementary material The online version of this article (10.1007/s00415-018-8752-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- X Armoiry
- Warwick Medical School, Division of Health Sciences, University of Warwick, Gibbet Hill Road, CV4 7AL, Coventry, England, UK.
| | - A Kan
- Warwick Medical School, Division of Health Sciences, University of Warwick, Gibbet Hill Road, CV4 7AL, Coventry, England, UK
| | - G J Melendez-Torres
- Warwick Medical School, Division of Health Sciences, University of Warwick, Gibbet Hill Road, CV4 7AL, Coventry, England, UK
| | - R Court
- Warwick Medical School, Division of Health Sciences, University of Warwick, Gibbet Hill Road, CV4 7AL, Coventry, England, UK
| | - P Sutcliffe
- Warwick Medical School, Division of Health Sciences, University of Warwick, Gibbet Hill Road, CV4 7AL, Coventry, England, UK
| | - P Auguste
- Warwick Medical School, Division of Health Sciences, University of Warwick, Gibbet Hill Road, CV4 7AL, Coventry, England, UK
| | - J Madan
- Warwick Medical School, Division of Health Sciences, University of Warwick, Gibbet Hill Road, CV4 7AL, Coventry, England, UK
| | - C Counsell
- Division of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland, UK
| | - A Clarke
- Warwick Medical School, Division of Health Sciences, University of Warwick, Gibbet Hill Road, CV4 7AL, Coventry, England, UK
| |
Collapse
|
2
|
|
3
|
Visser E, Wilde K, Yong KK, Wilson JF, Counsell C. O5-2.3 A new multiple sclerosis prevalence study in Aberdeen city, Orkney and Shetland. Br J Soc Med 2011. [DOI: 10.1136/jech.2011.142976b.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
4
|
Counsell C, Gordon J, Primrose W, Harris C, Caslake R. PATH52 Parkinsonism incidence in north-east Scotland: the PINE study. Journal of Neurology, Neurosurgery & Psychiatry 2010. [DOI: 10.1136/jnnp.2010.226340.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
5
|
Abstract
BACKGROUND Measuring cerebrospinal fluid (CSF) opening pressure by lumbar puncture (LP) is an essential tool in the investigation of patients with acute headache. AIM To assess documentation of opening CSF pressure in those with acute headache undergoing LP. General documentation of the procedure and CSF investigations was also assessed. METHODS Retrospective review of medical records of patients admitted to a teaching hospital Acute Medical Admissions Unit over a three-month period with a presenting complaint of headache. RESULTS A total of 106 patients presented with headache of whom 48 patients had at least one LP attempted. Only 41 patients (85%, 95% CI 72-94) had their LP documented. Of 47 patients that had a successful LP, 22 (47%) had a recorded opening pressure. Eighteen (32%) of all patients had their position recorded, with seven (15%) patients having had position and opening pressure documented. Twenty patients (43%) had the appropriate results documented. Twelve patients (31%) had paired serum glucose measured. CONCLUSIONS Documentation of a LP for headache in the acute setting was generally poor. CSF opening pressure measurement was frequently omitted and no appropriate action taken if high. Paired serum glucose was rarely measured. Acute physicians may benefit from a proposed protocol and documentation sticker.
Collapse
Affiliation(s)
- R Hewett
- Department of Clinical Neurosciences, Western General Hospital, Edinburgh, UK.
| | | |
Collapse
|
6
|
Peddie VL, Porter M, Counsell C, Caie L, Pearson D, Bhattacharya S. 'Not taken in by media hype': how potential donors, recipients and members of the general public perceive stem cell research. Hum Reprod 2009; 24:1106-13. [PMID: 19168873 PMCID: PMC2667789 DOI: 10.1093/humrep/den496] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2008] [Revised: 12/08/2008] [Accepted: 12/10/2008] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Views of embryo donors, scientists and members of the general public on embryonic stem cell research (eSCR) have been widely reported. Less is known about views of potential beneficiaries of stem cell therapy and the influence of media 'hype' on perceptions of eSCR among different groups of stakeholders. This study aimed to examine the perceptions of members of the general public as well as two patient groups likely to benefit from eSCR and to explore the role of the media in shaping these views. METHODS A qualitative study carried out in Aberdeen, Scotland included 15 people living with Parkinson's disease (PD), 15 people living with diabetes mellitus (DM), 15 couples with infertility and 21 members of the general public who volunteered for the study. Interview transcripts were analysed thematically using grounded theory. RESULTS The two patient groups likely to benefit from eSCR in the future differed in their knowledge (mainly gained from the media) and understanding of eSCR. Those living with PD were older, more debilitated and better informed than those with DM who showed limited interest in potential future benefits of eSCR. Infertile couples learnt about eSCR from health professionals who explained the process of embryo donation to them, and had sought no further information. Most of the general public had accessed information on eSCR and believed themselves to be more discerning than others because of their objectivity, intelligence and 'scientific awareness'. Although, the media and internet were primary sources of information for all except couples with infertility, members of all four groups claimed not to be taken in by the media 'hype' surrounding eSCR. CONCLUSIONS Those who expected to benefit from eSCR in the future as well as members of the general public differ in their susceptibility to media 'hype', while believing that they are not taken in by exaggerated claims of benefits. As respondents were a selected group who were not drawn from a representative sample, the findings cannot be generalized to a wider population.
Collapse
Affiliation(s)
- V L Peddie
- Obstetrics and Gynaecology, Division of Applied Health Sciences, University of Aberdeen, School of Medicine and Dentistry, Aberdeen AB25 2ZD, UK.
| | | | | | | | | | | |
Collapse
|
7
|
Caslake R, Moore JN, Gordon JC, Harris CE, Counsell C. Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism. J Neurol Neurosurg Psychiatry 2008; 79:1202-7. [PMID: 18469029 DOI: 10.1136/jnnp.2008.144501] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Accurate diagnosis of the cause of parkinsonism during life can be difficult, particularly at presentation, but few studies have described changes in clinical diagnosis over time and the effect of applying strict research criteria. METHODS Incident patients with a possible/probable diagnosis of degenerative or vascular parkinsonism had a standardised assessment at diagnosis and at yearly intervals thereafter at which the most likely clinical diagnosis was recorded without strict application of research criteria. Four years after the beginning of the incident period, formal research criteria were applied retrospectively using patient records at baseline and the latest yearly follow-up. RESULTS Of 82 incident patients, 66 underwent at least 1 year of follow-up. After a median follow-up of 29 months, clinical diagnosis had changed in 22 (33%). Most (82%) changes occurred in the first year and were due to the development of atypical clinical features, particularly early cognitive impairment; the results of brain imaging; responsiveness to levodopa; and the rate of disease progression. Diagnosis on research criteria differed from latest clinical diagnosis in eight participants (12%). Research criteria gave a "probable" diagnosis in 71% of parkinsonian patients at follow-up but in only 15% at the initial assessment. DISCUSSION The clinical diagnosis of the cause of parkinsonism at presentation was often incorrect, even when made by those with a special interest. In particular, Parkinson's disease was overdiagnosed. Research criteria were often unhelpful in clarifying the diagnosis, even after a median of 29 months of follow-up. Further research is required to identify factors that may be used to improve the accuracy of diagnosis at initial assessment.
Collapse
Affiliation(s)
- R Caslake
- Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen, UK
| | | | | | | | | |
Collapse
|
8
|
Asimakopoulos P, Caslake R, Harris CE, Gordon JC, Taylor KSM, Counsell C. Changes in quality of life in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2008; 79:716-8. [PMID: 18223017 DOI: 10.1136/jnnp.2007.137190] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND The issue of whether to adopt a "wait and watch" strategy or to initiate drug therapy soon after diagnosis in Parkinson's disease (PD) has been the subject of some debate. A recent observational study supported early treatment by demonstrating deterioration in self-reported health status in those left untreated, but not those who received therapy. We aimed to replicate this observation. METHODS People with PD from a prospective incidence study underwent follow-up with yearly clinical assessment of parkinsonian impairment (Unified Parkinson's Disease Rating Scale (UPDRS)) and self-reported health status (Parkinson's Disease Questionnaire (PDQ-39)). Two year outcomes were compared with those who started treatment within 1 year of diagnosis and those left untreated. RESULTS 42 patients with PD were followed-up for 2 years, of whom 26 started treatment during the first year and 16 remained untreated. Those receiving treatment had significantly higher UPDRS and PDQ-39 scores at baseline. There was no significant deterioration in PDQ-39 score in either group (median change untreated 0.8 vs treated 4.0; p = 0.47), despite a significant difference in the change in motor UPDRS scores (untreated 6.0 vs treated -6.0; p = 0.03). CONCLUSION Given the lack of significant deterioration in the PDQ-39 in untreated patients, we believe a "wait and watch" strategy for the treatment of newly diagnosed PD remains a credible approach unless randomised trials prove otherwise.
Collapse
|
9
|
Reid JM, Gubitz GJ, Dai D, Reidy Y, Christian C, Counsell C, Dennis M, Phillips SJ. External validation of a six simple variable model of stroke outcome and verification in hyper-acute stroke. J Neurol Neurosurg Psychiatry 2007; 78:1390-1. [PMID: 18024695 PMCID: PMC2095598 DOI: 10.1136/jnnp.2007.118802] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
We aimed to validate a previously described six simple variable (SSV) model that was developed from acute and sub-acute stroke patients in our population that included hyper-acute stroke patients. A Stroke Outcome Study enrolled patients from 2001 to 2002. Functional status was assessed at 6 months using the modified Rankin Scale (mRS). SSV model performance was tested in our cohort. 538 acute ischaemic (87%) and haemorrhagic stroke patients were enrolled, 51% of whom presented to hospital within 6 h of symptom recognition. At 6 months post-stroke, 42% of patients had a good outcome (mRS < or = 2). Stroke patients presenting within 6 h of symptom recognition were significantly older with higher stroke severity. In our Stroke Outcome Study dataset, the SSV model had an area under the curve of 0.792 for 6 month outcomes and performed well for hyper-acute or post-acute stroke, age < or > or = 75 years, haemorrhagic or ischaemic stroke, men or women, moderate and severe stroke, but poorly for mild stroke. This study confirms the external validity of the SSV model in our hospital stroke population. This model can therefore be utilised for stratification in acute and hyper-acute stroke trials.
Collapse
Affiliation(s)
- J M Reid
- Institute of Neurological Sciences, 1345 Govan Road, Glasgow G51 4TF, Scotland, UK.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Dick FD, De Palma G, Ahmadi A, Scott NW, Prescott GJ, Bennett J, Semple S, Dick S, Counsell C, Mozzoni P, Haites N, Wettinger SB, Mutti A, Otelea M, Seaton A, Söderkvist P, Felice A. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med 2007; 64:666-72. [PMID: 17332139 PMCID: PMC2078401 DOI: 10.1136/oem.2006.027003] [Citation(s) in RCA: 171] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE To investigate the associations between Parkinson's disease and other degenerative parkinsonian syndromes and environmental factors in five European countries. METHODS A case-control study of 959 prevalent cases of parkinsonism (767 with Parkinson's disease) and 1989 controls in Scotland, Italy, Sweden, Romania and Malta was carried out. Cases were defined using the United Kingdom Parkinson's Disease Society Brain Bank criteria, and those with drug-induced or vascular parkinsonism or dementia were excluded. Subjects completed an interviewer-administered questionnaire about lifetime occupational and hobby exposure to solvents, pesticides, iron, copper and manganese. Lifetime and average annual exposures were estimated blind to disease status using a job-exposure matrix modified by subjective exposure modelling. Results were analysed using multiple logistic regression, adjusting for age, sex, country, tobacco use, ever knocked unconscious and family history of Parkinson's disease. RESULTS Adjusted logistic regression analyses showed significantly increased odds ratios for Parkinson's disease/parkinsonism with an exposure-response relationship for pesticides (low vs no exposure, odds ratio (OR) = 1.13, 95% CI 0.82 to 1.57, high vs no exposure, OR = 1.41, 95% CI 1.06 to 1.88) and ever knocked unconscious (once vs never, OR = 1.35, 95% CI 1.09 to 1.68, more than once vs never, OR = 2.53, 95% CI 1.78 to 3.59). Hypnotic, anxiolytic or antidepressant drug use for more than 1 year and a family history of Parkinson's disease showed significantly increased odds ratios. Tobacco use was protective (OR = 0.50, 95% CI 0.42 to 0.60). Analyses confined to subjects with Parkinson's disease gave similar results. CONCLUSIONS The association of pesticide exposure with Parkinson's disease suggests a causative role. Repeated traumatic loss of consciousness is associated with increased risk.
Collapse
Affiliation(s)
- F D Dick
- Dr F Dick, Department of Environmental and Occupational Medicine, Aberdeen University Medical School, Foresterhill, Aberdeen AB25 2ZP, UK;
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
|
12
|
Hankey GJ, Sandercock P, Counsell C, Stobbs S. Low-Molecular-Weight Heparins or Heparinoids Versus Standard Unfractionated Heparin for Acute Ischemic Stroke. Stroke 2005. [DOI: 10.1161/01.str.0000176587.45249.50] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Graeme J. Hankey
- From the Department of Clinical Neurosciences (P.S., S.L.S.), Neurosciences Trials Unit, University of Edinburgh; and University of Aberdeen (C.C.), UK
| | - P. Sandercock
- From the Department of Clinical Neurosciences (P.S., S.L.S.), Neurosciences Trials Unit, University of Edinburgh; and University of Aberdeen (C.C.), UK
| | - C. Counsell
- From the Department of Clinical Neurosciences (P.S., S.L.S.), Neurosciences Trials Unit, University of Edinburgh; and University of Aberdeen (C.C.), UK
| | - S.L. Stobbs
- From the Department of Clinical Neurosciences (P.S., S.L.S.), Neurosciences Trials Unit, University of Edinburgh; and University of Aberdeen (C.C.), UK
| |
Collapse
|
13
|
Abstract
BACKGROUND Low-molecular-weight heparins and heparinoids are anticoagulants that may be associated with lower risks of haemorrhage and more powerful antithrombotic (anti-clotting) effects than standard unfractionated heparin. OBJECTIVES The objective of this review was to compare the effects of low-molecular-weight heparins or heparinoids with those of unfractionated heparin in people with acute, confirmed or presumed, ischaemic stroke (sudden blockage of an artery carrying blood to the brain). SEARCH STRATEGY We searched the Cochrane Stroke Group trials register (last searched November 2003). In addition we searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2003), MEDLINE (1966 to October 2003) and EMBASE (1980 to October 2003). For previous versions of this review we searched MedStrategy (1995) and also contacted pharmaceutical companies. SELECTION CRITERIA Randomised trials comparing heparinoids or low-molecular-weight heparins with standard unfractionated heparin in people with acute ischaemic stroke. Only trials where treatment was started within 14 days of stroke onset were included. DATA COLLECTION AND ANALYSIS Two reviewers independently selected studies for inclusion, assessed trial quality and extracted the data. MAIN RESULTS Six trials involving 740 people were included. Four trials compared a heparinoid (danaparoid), one trial compared a low-molecular-weight heparin (enoxaparin), and one trial compared an unspecified low-molecular-weight heparin with standard unfractionated heparin. Allocation a to low-molecular-weight heparin or heparinoid was associated with a significant reduction in the odds of deep vein thrombosis (Peto odds ratio 0.52, 95% confidence interval 0.56 to 0.79). However, the number of more major events (pulmonary embolism, death, intra-cranial or extra-cranial haemorrhage) was too small to provide a reliable estimate of more important benefits and risks. No information was reported for recurrent stroke or functional outcome. AUTHORS' CONCLUSIONS Treatment with a low-molecular-weight heparin or heparinoid after acute ischaemic stroke appears to decrease the occurrence of deep vein thrombosis compared to standard unfractionated heparin, but there are too few data to provide reliable information on their effects on other important outcomes, including death and intracranial haemorrhage.
Collapse
Affiliation(s)
- P Sandercock
- Department of Clinical Neurosciences, Neurosciences Trials Unit, Bramwell Dott Building, Western General Hospital, Crewe Road, Edinburgh, UK, EH4 2XU.
| | | | | |
Collapse
|
14
|
Counsell C, Dennis M, McDowall M. Predicting functional outcome in acute stroke: comparison of a simple six variable model with other predictive systems and informal clinical prediction. J Neurol Neurosurg Psychiatry 2004; 75:401-5. [PMID: 14966155 PMCID: PMC1738951 DOI: 10.1136/jnnp.2003.018085] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Statistical models that predict functional outcome after stroke using six simple variables (SSV) have recently been developed and validated. OBJECTIVE To compare the accuracy of these models with other simple ways of predicting outcome soon after stroke. METHODS The SSV model for being alive and independent (modified Rankin score < or =2) six months or one year after stroke was compared with predictions based on a model that included only age and Oxford community stroke project classification, with predictions based on conscious level and urinary continence, and with informal clinical predictions made by clinicians interested in stroke. Predictions were compared in an independent hospital based cohort of stroke patients using receiver operator characteristic (ROC) curves. RESULTS The SSV model at six months had a significantly greater area under the curve (0.84) than the model with only age and stroke classification (0.75). Predictions based on conscious level and urinary continence were no better than those of the SSV model and were unable to predict subjects with a high probability of good outcome. The sensitivity and specificity for informal clinical predictions at one year lay on or below the SSV model curve, implying that the SSV model was at least as good as clinical predictions. CONCLUSIONS The SSV models performed as well as or better than other simple predictive systems. These models will be useful in epidemiological studies but should not be used to guide clinical management until their impact on patient care and outcome has been evaluated.
Collapse
Affiliation(s)
- C Counsell
- Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK.
| | | | | |
Collapse
|
15
|
Abstract
BACKGROUND Most ischaemic strokes are caused by blood clots blocking an artery in the brain. Clot prevention with anticoagulant therapy could have a significant impact on patient survival, disability and stroke recurrence. OBJECTIVES The objective of this review was to assess the effect of anticoagulant therapy versus control in the early treatment of patients with acute ischaemic stroke. SEARCH STRATEGY We searched the Cochrane Stroke Group trials register (last searched 30 October 2003). For previous updates of this review, we searched the register of the Antithrombotic Trialists' (ATT) Collaboration, consulted MedStrategy (1995), and contacted relevant drug companies. SELECTION CRITERIA Randomised trials comparing early anticoagulant therapy (started within two weeks of stroke onset) with control in patients with acute presumed or confirmed ischaemic stroke. DATA COLLECTION AND ANALYSIS Two reviewers independently selected trials for inclusion, assessed trial quality and extracted the data. MAIN RESULTS Twenty-two trials involving 23,547 patients were included. The quality of the trials varied considerably. The anticoagulants tested were standard unfractionated heparin, low-molecular-weight heparins, heparinoids, oral anticoagulants, and thrombin inhibitors. Based on nine trials (22,570 patients) there was no evidence that anticoagulant therapy reduced the odds of death from all causes (odds ratio (OR) = 1.05, 95% confidence interval (CI) 0.98 to 1.12) at the end of follow-up. Similarly, based on six trials (21,966 patients), there was no evidence that anticoagulants reduced the odds of being dead or dependent at the end of follow-up (OR = 0.99; 95% CI 0.93 to 1.04). Although anticoagulant therapy was associated with about 9 fewer recurrent ischaemic strokes per 1000 patients treated (OR = 0.76; 95% CI 0.65 to 0.88), it was also associated with a similar sized 9 per 1000 increase in symptomatic intracranial haemorrhages (OR = 2.52; 95% CI 1.92 to 3.30). Similarly, anticoagulants avoided about 4 pulmonary emboli per 1000 (OR = 0.60, 95% CI 0.44 to 0.81), but this benefit was offset by an extra 9 major extracranial haemorrhages per 1000 (OR = 2.99; 95% CI 2.24 to 3.99). Sensitivity analyses did not identify a particular type of anticoagulant regimen or patient characteristic associated with net benefit. REVIEWERS' CONCLUSIONS Immediate anticoagulant therapy in patients with acute ischaemic stroke is not associated with net short- or long-term benefit. The data from this review do not support the routine use of any type of anticoagulant in acute ischaemic stroke. People treated with anticoagulants had less chance of developing deep vein thrombosis (DVT) and pulmonary embolism (PE) following their stroke, but these sorts of blood clots are not very common, and may be prevented in other ways.
Collapse
|
16
|
Abstract
BACKGROUND In patients with acute ischaemic stroke, platelets become activated. Antiplatelet therapy might reduce the volume of brain damaged by ischaemia and reduce the risk of early recurrent ischaemic stroke. This might reduce the risk of early death and improve long-term outcome in survivors. However, antiplatelet therapy might also increase the risk of fatal or disabling intracranial haemorrhage. OBJECTIVES The aim of this review is to assess the efficacy and safety of antiplatelet therapy in acute ischaemic stroke. SEARCH STRATEGY We searched the Cochrane Stroke Group Trials Register (last searched August 2002), the Cochrane Controlled Trials Register (CCTR) (Cochrane Library Issue 1 2002), MEDLINE (June 1998-October 2001), and EMBASE (June 1998-February 2002). In 1998, for previous versions of this review, we searched the register of the Antiplatelet Trialists Collaboration, MedStrategy and contacted relevant drug companies. SELECTION CRITERIA Randomised trials comparing antiplatelet therapy (started within 14 days of the stroke) with control in patients with definite or presumed ischaemic stroke. DATA COLLECTION AND ANALYSIS Two reviewers independently applied the inclusion criteria and assessed trial quality, and for the included trials, extracted and cross-checked the data. MAIN RESULTS Nine trials involving 41,399 patients were included. Two trials testing aspirin 160 to 300 mg once daily started within 48 hours of onset contributed 98% of the data. The maximum follow-up was six months. With treatment, there was a significant decrease in death or dependency at the end of follow-up (OR = 0.94; 95% CI 0.91 to 0.98). In absolute terms, 13 more patients were alive and independent at the end of follow-up for every 1000 patients treated. Furthermore, treatment increased the odds of making a complete recovery from the stroke (OR = 1.06; 95% CI 1.01 to 1.11). In absolute terms, 10 more patients made a complete recovery for every 1000 patients treated. Antiplatelet therapy was associated with a small but definite excess of 2 symptomatic intracranial haemorrhages for every 1000 patients treated, but this was more than offset by a reduction of 7 recurrent ischaemic strokes and about one pulmonary embolus for every 1000 patients treated. REVIEWER'S CONCLUSIONS Antiplatelet therapy with aspirin 160 to 300 mg daily, given orally (or per rectum in patients who cannot swallow), and started within 48 hours of onset of presumed ischaemic stroke reduces the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications and improves long-term outcome.
Collapse
Affiliation(s)
- P Sandercock
- Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK, EH4 2XU.
| | | | | | | |
Collapse
|
17
|
Sandercock P, Mielke O, Liu M, Counsell C. Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev 2003:CD000248. [PMID: 12535394 DOI: 10.1002/14651858.cd000248] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND After a first ischaemic stroke, further vascular events due to thromboembolism (especially myocardial infarction and recurrent stroke) are common and often fatal. Anticoagulants could potentially reduce the risk of such events, but any benefits could be offset by an increased risk of fatal or disabling haemorrhages. OBJECTIVES The objective of this review was to assess the effect of prolonged anticoagulant therapy (compared with placebo or open control) following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. SEARCH STRATEGY We searched the Cochrane Stroke Group trials register. We contacted companies marketing anticoagulant agents. The most recent search for this review was carried out in August 2002. SELECTION CRITERIA Randomised and quasi-randomised trials comparing at least one month of anticoagulant therapy with control in people with previous presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. DATA COLLECTION AND ANALYSIS Two reviewers independently selected trials for inclusion, assessed trial quality and extracted the data. MAIN RESULTS Eleven trials involving 2487 patients were included. The quality of the 9 trials which predated routine computerised tomography scanning and the use of the International Normalised Ratio to monitor anticoagulation was poor. There was no evidence of an effect of anticoagulant therapy on either the odds of death or dependency (two trials, odds ratio 0.83, 95% confidence interval [CI] 0.52 to 1.34) or of 'non-fatal stroke, myocardial infarction, or vascular death' (four trials, odds ratio 0.96, 95% CI 0.68-1.37). Death from any cause (odds ratio 0.95, 95% CI 0.73 to 1.24) and death from vascular causes (odds ratio 0.86, 95% CI 0.66 to 1.13) were not significantly different between treatment and control. The inclusion of two recent completed trials did not alter these conclusions. There was no evidence of an effect of anticoagulant therapy on the risk of recurrent ischaemic stroke (odds ratio 0.85, 95% CI 0.66 to 1.09). However, anticoagulants increased fatal intracranial haemorrhage (odds ratio 2.54, 95% CI 1.19 to 5.45), and major extracranial haemorrhage (odds ratio 3.43, 95% CI 1.94 to 6.08). This is equivalent to anticoagulant therapy causing about 11 additional fatal intracranial haemorrhages and 25 additional major extracranial haemorrhages per year for every 1000 patients given anticoagulant therapy. REVIEWER'S CONCLUSIONS Compared with control, there was no evidence of benefit from long-term anticoagulant therapy in people with presumed non-cardioembolic ischaemic stroke or transient ischaemic attack, but there was a significant bleeding risk.
Collapse
Affiliation(s)
- P Sandercock
- Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK, EH4 2XU.
| | | | | | | |
Collapse
|
18
|
Abstract
BACKGROUND Fibrinogen depleting agents reduce fibrinogen in blood plasma, reduce blood viscosity and hence increase blood flow. This may help remove the blood clot blocking the artery and re-establish blood flow to the affected area of the brain after an ischaemic stroke. The risk of haemorrhage may be less than with thrombolytic agents. OBJECTIVES The objective of this review was to assess the effect of fibrinogen depleting agents in patients with acute ischaemic stroke. SEARCH STRATEGY We searched the Cochrane Stroke Group Trials Register (last searched May 2003). In addition we searched the following electronic databases: EMBASE (1980-October 2001), China Biological Medicine Database (CBM-disc 1981- December 2002), Chinese Stroke Trials Register (1996 - December 2002) and Index of Scientific and Technical Proceedings (Web of Science Proceedings [1990-October 2001]). We handsearched relevant journals and contacted Chinese and Japanese researchers and drug companies. SELECTION CRITERIA Randomised and quasi-randomised trials of fibrinogen depleting agents started within 14 days of stroke onset, compared with control in patients with definite or possible ischaemic stroke. DATA COLLECTION AND ANALYSIS Two reviewers independently applied the inclusion criteria, assessed trial quality and extracted the data. MAIN RESULTS Five trials involving 2926 patients were included. A further trial (ESTAT) has not yet been published in full. Four trials tested ancrod and one trial tested defibrase. Allocation concealment was adequate in four trials. Fibrinogen depleting agents moderately reduced the proportion of patients who were dead or disabled at the end of follow up (Relative risk [RR] 0.90, 95% Confidence Interval [CI] 0.82 to 0.98, 2P=0.02). There was no statistically significant difference in death from all causes during the scheduled treatment period (RR 0.71, 95% CI 0.44 to 1.13) and at the end of follow-up (RR 0.98, 95% CI 0.78 to 1.24). There was a non-significant excess of symptomatic intracranial haemorrhages with treatment (RR 2.64, 95%CI 0.96 to 7.30, 2P=0.06). REVIEWER'S CONCLUSIONS Fibrinogen depleting agents are promising. However more data, particularly ESTAT data, are needed before more reliable conclusions can be drawn.
Collapse
Affiliation(s)
- M Liu
- Department of Neurology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan province, China
| | | | | | | |
Collapse
|
19
|
Abstract
Prognostic models in stroke may be useful in clinical practice and research. We systematically reviewed the methodology and results of studies that have identified independent predictors of survival, independence in activities of daily living, and getting home in patients with acute stroke. Eligible studies (published in full in English) included at least 100 patients in whom at least 3 predictor variables were assessed within 30 days of stroke onset and who were followed up for at least 30 days. We recorded 25 indicators of the validity and practicality of each model and identified variables that were consistent independent predictors of each outcome. Eighty-three separate prognostic models were found but most had potentially serious deficiencies in internal and statistical validity, many had limited generalisability, and none had been adequately validated. Only 4 studies met 8 simple quality criteria. Over 150 different predictor variables have been analysed but most were assessed in only 1 or 2 models. None of the existing prognostic models have been sufficiently well developed and validated to be useful in either clinical practice or research. Better quality models must be produced to enable, for example, adequate case-mix correction when comparing outcome among different groups of stroke patients.
Collapse
Affiliation(s)
- C Counsell
- Department of Clinical Neurosciences, Western General Hospital, Edinburgh, UK
| | | |
Collapse
|
20
|
Bond R, Rerkasem K, Counsell C, Salinas R, Naylor R, Warlow CP, Rothwell PM. Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting). Cochrane Database Syst Rev 2002:CD000190. [PMID: 12076386 DOI: 10.1002/14651858.cd000190] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND Temporary interruption of cerebral blood flow during carotid endarterectomy can be avoided by using a shunt across the clamped section of the carotid artery. This may improve outcome. OBJECTIVES The objective of this review was to assess the effect of routine versus selective, or never, shunting during carotid endarterectomy, and to assess the best method for selecting patients for shunting. SEARCH STRATEGY For the original review the authors searched the Cochrane Stroke Group trials register, Medline (1966 to 1994), Embase (1980 to 1995) and Index to Scientific and Technical Proceedings (1980 to 1994). They also hand searched Annals of Surgery (1981 to 1995), British Journal of Surgery (1985 to 1995), European Journal of Vascular Surgery (1988 to 1995) and World Journal of Surgery (1978 to 1995). For the updated review, for the dates January 1994 - December 2000 we: 1. Repeated all these searches performed for the original review and developed more comprehensive search strategies for Medline and Embase. The Cochrane Stroke Group Trials Register was last searched in May 2001. 2. Hand searched the Journal of Vascular Surgery, Stroke, Annals of Vascular Surgery, American Journal of Surgery and Cardiovascular Surgery. 3. Hand searched the abstracts from the International Stroke Conference, AGM of the Vascular Surgical Society (UK), AGM of the Association of Surgeons of Great Britain and Ireland and the Annual Meeting of the Society for Vascular Surgery (USA). 4. Searched reference lists from all relevant trials All the authors of studies included in the initial review, and other authors known to have published relevant work, were contacted requesting information about further published or unpublished data. SELECTION CRITERIA Randomised and quasi-randomised trials of routine shunting compared with no shunting or selective shunting, and trials that compared different shunting policies in patients undergoing carotid endarterectomy. DATA COLLECTION AND ANALYSIS For the original review two reviewers independently performed the searches and applied the inclusion criteria. The data were extracted by one reviewer and double-checked. Trial quality was assessed. During the update, two reviewers independently performed the searches and applied the inclusion criteria. No new relevant randomised controlled trials were found. MAIN RESULTS Despite recommendation from the original review that further studies were required, no new trials of adequate quality and fitting the inclusion criteria were found. The initial review included three trials. Two trials involving 590 patients compared routine shunting with no shunting. The other trial involving 131 patients compared shunting with a combination of electroencephalographic and carotid pressure measurement, with shunting by carotid pressure measurement alone. Allocation was adequately concealed in one trial, and one trial was quasi-randomised. Analysis was by intention-to-treat where possible. For routine versus no shunting, there was no significant difference in the rate of all stroke, ipsilateral stroke or death up to 30 days after surgery, although data were limited. There was no significant difference between the risk of ipsilateral stroke in patients selected for shunting with the combination of electroencephalographic and carotid pressure assessment compared to pressure assessment alone, although again the data were limited. REVIEWER'S CONCLUSIONS When first published in 1995, this review concluded that the data available were too limited to either support or refute the use of routine or selective shunting in carotid endarterectomy. It was suggested that large scale randomised trials using no shunting as the control group were required. No one method of monitoring in selective shunting has been shown to produce better outcomes. No further prospective randomised or quasi-randomised trials have been performed since then and the conclusions therefore remain unchanged.
Collapse
Affiliation(s)
- R Bond
- Stroke Prevention Unit, Department of Clinical Neurology, Radcliffe Infirmary Hospital, Woodstock Road, Oxford, Oxfordshire, UK, OX9 3LL.
| | | | | | | | | | | | | |
Collapse
|
21
|
|
22
|
|
23
|
Elia G, Counsell C, Singer SJ. Uterine artery malformation as a hidden cause of severe uterine bleeding. A case report. J Reprod Med 2001; 46:398-400. [PMID: 11354845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
BACKGROUND Uterine artery malformations are rare, life-threatening conditions. Clinical suspicion is essential for a prompt diagnosis and treatment. CASE A 29-year-old woman was evaluated for severe uterine bleeding that started abruptly two weeks after elective termination of pregnancy. She underwent dilatation and curettage of the uterine cavity for retained products of conception. The patient presented to the emergency room two weeks later with abrupt onset of profuse vaginal bleeding that would spontaneously subside. Magnetic resonance angiography revealed a left uterine artery malformation that was successfully embolized. CONCLUSION Uterine artery malformations should be suspected when heavy vaginal bleeding occurs in spite of medical or surgical treatment.
Collapse
Affiliation(s)
- G Elia
- Division of Urogynecology, Department of Obstetrics and Gynecology, St. Luke's-Roosevelt Hospital Center, 1000 Tenth Avenue, Suite 10C, New York, NY 10019, USA.
| | | | | |
Collapse
|
24
|
Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, Xie JX, Warlow C, Peto R. Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31:1240-9. [PMID: 10835439 DOI: 10.1161/01.str.31.6.1240] [Citation(s) in RCA: 463] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND AND PURPOSE Long-term daily aspirin is of benefit in the years after ischemic stroke, and 2 large randomized trials (the Chinese Acute Stroke Trial [CAST] and the International Stroke Trial [IST]), with 20 000 patients in each, have shown that starting daily aspirin promptly in patients with suspected acute ischemic stroke also reduces the immediate risk of further stroke or death in hospital and the overall risk of death or dependency. However, some uncertainty remains about the effects of early aspirin in particular categories of patient with acute stroke. METHODS To assess the balance of benefits and risks of aspirin in particular categories of patient with acute stroke (eg, the elderly, those without a CT scan, or those with atrial fibrillation), a prospectively planned meta-analysis is presented of the data from 40 000 individual patients from both trials on events that occurred in the hospital during the scheduled treatment period (4 weeks in CAST, 2 weeks in IST), with 10 characteristics used to define 28 subgroups. This represents 99% of the worldwide evidence from randomized trials. RESULTS There was a highly significant reduction of 7 per 1000 (SD 1) in recurrent ischemic stroke (320 [1.6%] aspirin versus 457 [2. 3%] control, 2P<0.000001) and a less clearly significant reduction of 4 (SD 2) per 1000 in death without further stroke (5.0% versus 5. 4%, 2P=0.05). Against these benefits, there was an increase of 2 (SD 1) per 1000 in hemorrhagic stroke or hemorrhagic transformation of the original infarct (1.0% versus 0.8%, 2P=0.07) and no apparent effect on further stroke of unknown cause (0.9% versus 0.9%). In total, therefore, there was a net decrease of 9 (SD 3) per 1000 in the overall risk of further stroke or death in hospital (8.2% versus 9.1%, 2P=0.001). For the reduction of one third in recurrent ischemic stroke, subgroup-specific analyses found no significant heterogeneity of the proportional benefit of aspirin (chi(2)(18)=20. 9, NS), even though the overall treatment effect (chi(2)(1)=24.8, 2P<0.000001) was sufficiently large for such subgroup analyses to be statistically informative. The absolute risk among control patients was similar in all 28 subgroups, so the absolute reduction of approximately 7 per 1000 in recurrent ischemic stroke does not differ substantially with respect to age, sex, level of consciousness, atrial fibrillation, CT findings, blood pressure, stroke subtype, or concomitant heparin use. There was no good evidence that the apparent decrease of approximately 4 per 1000 in death without further stroke was reversed in any subgroup or that in any subgroup the increase in hemorrhagic stroke was much larger than the overall average of approximately 2 per 1000. Finally, there was no significant heterogeneity between the reductions in the composite outcome of any further stroke or death (chi(2)(18)=16.5, NS). Among the 9000 patients (22%) randomized without a prior CT scan, aspirin appeared to be of net benefit with no unusual excess of hemorrhagic stroke; moreover, even among the 800 (2%) who had inadvertently been randomized after a hemorrhagic stroke, there was no evidence of net hazard (further stroke or death, 63 aspirin versus 67 control). CONCLUSIONS Early aspirin is of benefit for a wide range of patients, and its prompt use should be routinely considered for all patients with suspected acute ischemic stroke, mainly to reduce the risk of early recurrence.
Collapse
Affiliation(s)
- Z M Chen
- Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
BACKGROUND Low molecular weight heparins and heparinoids may be associated with lower risks of haemorrhage and more powerful antithrombotic effects than standard unfractionated heparin. OBJECTIVES The objective of this review was to compare the effects of low molecular weight heparins or heparinoids with those of unfractionated heparin in people with acute confirmed or presumed ischaemic stroke. SEARCH STRATEGY We searched the Cochrane Stroke Group trials register and MedStrategy (1995). We also contacted pharmaceutical companies. Date of most recent search: April 1999. SELECTION CRITERIA Randomised trials comparing heparinoids or low molecular weight heparins with standard unfractionated heparin in people with acute ischaemic stroke. Only trials where treatment was started within 14 days of stroke onset were included. DATA COLLECTION AND ANALYSIS Two reviewers independently selected studies for inclusion, assessed trial quality and extracted the data. MAIN RESULTS Five trials involving 705 people were included. Four trials compared a heparinoid (danaparoid), and one compared a low molecular weight heparin (enoxaparin), with standard unfractionated heparin. Overall, 55/414 (13%) of the patients allocated danaparoid or enoxaparin had deep vein thrombosis compared with 65/291 (22%) of those allocated unfractionated heparin. This reduction was significant (odds ratio 0.52, 95% confidence interval 0.56 - 0.79). However, the number of more major events (pulmonary embolism, death, intra-cranial or extra-cranial haemorrhage) was too small to provide a reliable estimate of more important benefits and risks. No information was reported for recurrent stroke or functional outcome in survivors. REVIEWER'S CONCLUSIONS Low molecular weight heparin or heparinoid appear to decrease the occurrence of deep vein thrombosis compared to standard unfractionated heparin, but there are too few data to provide reliable information on their effect on other important outcomes, including death and intracranial haemorrhage.
Collapse
Affiliation(s)
- C Counsell
- Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK, EH4 2XU.
| | | |
Collapse
|
26
|
Abstract
BACKGROUND Some surgeons who use carotid patching favour using the saphenous vein, whilst others favour synthetic materials. OBJECTIVES The objective of this review was to assess the effect of different materials for carotid patch angioplasty. SEARCH STRATEGY We searched the Cochrane Stroke Group trials register, Medline (1966 to 1995), Embase (1980 to 1995) and Index to scientific and technical proceedings (1980 to 1994). We handsearched Annals of Surgery (1981 to 1995), British Journal of Surgery (1985 to 1995), European Journal of Vascular and Endovascular Surgery (1987 to 1995) and World Journal of Surgery (1978 to 1995). SELECTION CRITERIA Randomised trials comparing one type of carotid patch with another for carotid endarterectomy. DATA COLLECTION AND ANALYSIS One reviewer applied the inclusion criteria and extracted the data. Trial quality was assessed. MAIN RESULTS Three trials involving 326 operations were included. The trials compared saphenous vein patches with synthetic polytetrafluroethylene patches. Allocation was not adequately concealed in two trials, and only one followed-up patients until hospital discharge. Intention-to-treat analysis was only possible for the latter trial. In all trials a patient could be randomised twice and have each carotid artery randomised to different treatment groups. One trial was excluded from the analyses of death and any stroke because it was not possible to clarify how many patients, rather than arteries, were allocated to each treatment. There were too few events to determine whether there was any difference between the patch materials for perioperative stroke, death and arterial complications. During longterm follow-up for more than one year, no difference was shown between the two types of patch for the risk of stroke, death, or arterial restenosis. However, the number of events was small. Based on 236 patients in two trials, there were significantly fewer pseudoaneurysms associated with synthetic patches (odds ratio 0.15, 95% confidence interval 0.05 to 0.44). REVIEWER'S CONCLUSIONS There is not enough evidence to differentiate between venous and synthetic patches in carotid endarterectomy.
Collapse
Affiliation(s)
- C Counsell
- Neurosciences Trials Unit, Department of Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh, UK, EH4 2XU.
| | | | | |
Collapse
|
27
|
Abstract
BACKGROUND Most ischaemic strokes are caused by blood clots blocking an artery in the brain. Clot prevention with anticoagulant therapy could have a significant impact on patient survival, disability and recurrence of stroke. OBJECTIVES The objective of this review was to assess the effect of anticoagulant therapy in the early treatment of patients with acute ischaemic stroke. SEARCH STRATEGY We searched the Cochrane Stroke Group trials register (most recent search: March 1999) and consulted MedStrategy (1995). We also contacted drug companies. SELECTION CRITERIA Randomised trials comparing early anticoagulant therapy (started within two weeks of stroke onset) with control in patients with acute presumed or confirmed ischaemic stroke. DATA COLLECTION AND ANALYSIS Two reviewers independently selected trials for inclusion, assessed trial quality and extracted the data. MAIN RESULTS Twenty-one trials involving 23,427 patients were included. The quality of the trials varied considerably. The anticoagulants tested were standard unfractionated heparin, low-molecular-weight heparins, heparinoids, oral anticoagulants, and thrombin inhibitors. Based on eight trials (22,450 patients) there was no evidence that anticoagulant therapy reduced the odds of death from all causes (odds ratio 1.05, 95% confidence intervals 0.98-1.12). Similarly, based on five trials (21, 846 patients), there was no evidence that anticoagulants reduced the odds of being dead or dependent at the end of follow-up (odds ratio 0.99, 95% confidence intervals 0.94-1.05). Although anticoagulant therapy was associated with about 9 fewer recurrent ischaemic strokes per 1000 patients treated, it was also associated with a similar sized 9 per 1000 increase in symptomatic intracranial haemorrhages. Similarly, anticoagulants avoided about 4 pulmonary emboli per 1000, but this benefit was offset by an extra 9 major extracranial haemorrhages per 1000. Sensitivity analyses did not identify a particular type of anticoagulant regimen or patient characteristic associated with net benefit. REVIEWER'S CONCLUSIONS Immediate anticoagulant therapy in patients with acute ischaemic stroke is not associated with net short- or long-term benefit. The data from this review do not support the routine use of any type of anticoagulant in acute ischaemic stroke.
Collapse
Affiliation(s)
- G Gubitz
- Department of Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh, UK, EH4 2XU.
| | | | | | | |
Collapse
|
28
|
Abstract
BACKGROUND Carotid endarterectomy reduces the risk of stroke in people with recently symptomatic, severe carotid artery stenosis. However, there are significant perioperative risks which may be lessened by performing the operation under local rather than general anaesthetic. OBJECTIVES The objective of this review was to assess the effect of endarterectomy under local compared with general anaesthetic. SEARCH STRATEGY We searched the Cochrane Stroke Group trials register, Medline (1966 to 1995), Embase (1980 to 1995), and Index to Scientific and Technical Proceedings (1980 to 1994). We handsearched Annals of Surgery (1981 to 1995), British Journal of Surgery (1985 to 1995), European Journal of Vascular Surgery (1988 to 1995) and World Journal of Surgery (1978 to 1995). Reference lists of articles were searched. SELECTION CRITERIA Randomised trials and non-randomised studies comparing carotid endarterectomy under local versus general anaesthetic. DATA COLLECTION AND ANALYSIS One reviewer selected studies for inclusion and another independently checked the decisions. Two reviewers assessed trial quality and independently extracted the data. MAIN RESULTS Three randomised trials involving 143 patients, and 17 non-randomised studies involving about 5970 patients were included. The methodological quality of the randomised trials was questionable. Two of the non-randomised studies were prospective and 12 reported on a consecutive series of patients. In nine non-randomised studies the number of patients, as opposed to the number of arteries, was unclear. There were insufficient data to enable conclusions to be drawn from the randomised trials. In 15 non-randomised studies, no significant difference was shown between local and general anaesthetic in deaths within 30 days of operation (odds ratio 0.61, 95% confidence interval 0.32 to 1.16). Non-randomised studies showed that local anaesthetic was associated with a significant reduction in the odds of stroke (15 studies), stroke or death (14 studies), myocardial infarction (12 studies), and pulmonary complications (five studies), within 30 days of the operation. Patient and surgeon satisfaction were not reported in any study. REVIEWER'S CONCLUSIONS There is not enough evidence from randomised trials comparing carotid endarterectomy performed under local as opposed to general anaesthetic. Non-randomised studies suggest potential benefits with local anaesthetic. However these studies are likely to be significantly biased.
Collapse
Affiliation(s)
- C Tangkanakul
- Neurosciences Trials Unit, Department of Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh, UK, EH4 2XU.
| | | | | |
Collapse
|
29
|
Abstract
BACKGROUND Carotid patch angioplasty (with either a venous or a synthetic patch) may reduce the risk of carotid artery restenosis and subsequent ischaemic stroke. OBJECTIVES The objective of this review was to assess the effect of routine or selective carotid patch angioplasty compared to carotid endarterectomy with primary closure. SEARCH STRATEGY We searched the Cochrane Stroke Group trials register, Medline (1966 to 1995), Embase (1980 to 1995) and Index to Scientific and Technical Proceedings (1980 to 1994). We handsearched Annals of Surgery (1981 to 1995), British Journal of Surgery (1985 to 1995), European Journal of Vascular and Endovascular Surgery (1987 to 1995) and World Journal of Surgery (1978 to 1995). SELECTION CRITERIA Randomised trials comparing carotid patch angioplasty with primary closure in any patients undergoing carotid endarterectomy. DATA COLLECTION AND ANALYSIS Two reviewers independently assessed eligibility, trial quality and extracted the data. MAIN RESULTS Six trials involving 794 patients and 882 operations were included. The quality of trials was generally poor. Follow-up varied from hospital discharge to five years. Carotid patch angioplasty showed a reduction in the risk of stroke of any type, ipsilateral stroke, and stroke or death, during the perioperative period and longterm follow-up. However, data were not available from all trials, the number of events was small and there was significant loss to follow-up. Patching appeared to reduce the risk of perioperative arterial occlusion (six trials, odds ratio 0.17, 95% confidence interval 0.06 to 0.46). Patching was also associated with decreased restenosis during longterm follow-up in five trials, (odds ratio 0.32, 95% confidence interval 0.19 to 0.53). However, these results are uncertain because of loss to follow-up and the small number of events. Very few arterial complications, including haemorrhage, infection, cranial nerve palsies and pseudo-aneurysm formation were recorded with either patch or primary closure. REVIEWER'S CONCLUSIONS Limited evidence suggests that carotid patch angioplasty may lower the risk of perioperative arterial occlusion and restenosis. It is unclear whether this reduces the risk of death or stroke.
Collapse
Affiliation(s)
- C Counsell
- Neurosciences Trials Unit, Department of Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh, UK, EH4 2XU.
| | | | | | | |
Collapse
|
30
|
Abstract
METHOD A systematic review of three bibliographic databases from 1986 to 1996 identified 78 papers reporting barriers to recruitment of clinicians and patients to randomised controlled trials. RESULTS Clinician barriers included: time constraints, lack of staff and training, worry about the impact on the doctor-patient relationship, concern for patients, loss of professional autonomy, difficulty with the consent procedure, lack of rewards and recognition, and an insufficiently interesting question. Patient barriers included: additional demands of the trial, patient preferences, worry caused by uncertainty, and concerns about information and consent. CONCLUSIONS To overcome barriers to clinician recruitment, the trial should address an important research question and the protocol and data collection should be as straightforward as possible. The demands on clinicians and patients should be kept to a minimum. Dedicated research staff may be required to support clinical staff and patients. The recruitment aspects of a randomised controlled trial should be carefully planned and piloted. Further work is needed to quantify the extent of problems associated with clinician and patient participation, and proper evaluation is required of strategies to overcome barriers.
Collapse
Affiliation(s)
- S Ross
- Health Services Research Unit, University of Aberdeen, United Kingdom
| | | | | | | | | | | |
Collapse
|
31
|
Abstract
OBJECTIVE To summarize the evidence from randomized controlled trials on the effects of cysticidal therapy used for treating human cysticercosis. METHODS Published and unpublished studies in any language identified through MEDLINE (1966 - June 1999) specialized databases, abstracts, proceedings and contact with experts were analysed. Those which compared, using randomized or quasi-randomized methods, any cysticidal drug with placebo or symptomatic therapy were entered in the study. Data were extracted independently by two reviewers and trial quality assessed. Meta-analysis using fixed effects models calculated provided there was no significant heterogeneity, expressed as relative risk. RESULTS Four trials met the inclusion criteria, treating intraparenchymatous neurocysticercosis with either albendazole or praziquantel compared to placebo or no treatment. In the two trials reporting clinical outcomes, treatment was not associated with a reduction in the risk of seizures, although numbers were small (RR 0.95, 95% CI 0.59-1.51). Four trials reported radiological outcomes, and cysticidal treatment was associated with a lower risk of cyst persistence of scans taken within six months of start of treatment (RR 0.83, 95% CI 0.70-0.99). Subsidiary analysis assuming different outcomes in patients lost to follow-up did not alter the findings of the main analysis. CONCLUSIONS There is insufficient evidence to determine whether cysticidal therapy is of any clinical benefit to patients with neurocysticercosis. The review does not exclude the possibility that more patients remain seizure-free when treated with cysticidal drugs. Further testing through placebo-controlled trials is required.
Collapse
Affiliation(s)
- R Salinas
- Ministry of Health, Santiago, Chile.
| | | | | | | | | |
Collapse
|
32
|
Abstract
BACKGROUND AND PURPOSE Research in acute stroke has expanded rapidly. Many potentially important interventions lack commercial potential (eg, admission to a stroke unit). We therefore wished to examine the frequency of reports of randomized trials of interventions for acute stroke over the past 40 years, the source of support for such trials, the reporting of the commercial involvement, and whether the proportion of commercially supported trials had changed. METHODS Eligible trials were identified from the Cochrane Stroke Group's specialized register of controlled clinical trials. We included all randomized trials in patients with acute stroke which published a full text report, in English, between 1955 and 1995. Two reviewers independently extracted data on the involvement of the pharmaceutical industry in all eligible trials. RESULTS There was a substantial increase in the number of acute stroke trials published per year between 1955 and 1995. The description of pharmaceutical industry involvement in each trial report was poor. Only a minority of supported trials made explicit statements about the role of the sponsoring company. The proportion of trials apparently supported by the pharmaceutical industry has increased substantially. CONCLUSIONS The increasingly important role of the pharmaceutical industry in evaluating new treatments gives substantial scope for bias and may not be in the interests of public health. Poor reporting of the sponsor's involvement suggests that modifications to the guidelines for the reporting of randomized controlled trials to include more details of the sponsor's involvement in the design, conduct, management, analysis, and reporting of the trial are justified.
Collapse
Affiliation(s)
- P J Dorman
- Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, UK
| | | | | |
Collapse
|
33
|
Counsell C, Gilbert M. Implementation of a nurse practitioner role in an acute care setting. Crit Care Nurs Clin North Am 1999; 11:277-82. [PMID: 10838989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
During the implementation, the authors strived to clearly identify a person to focus on patient outcomes. Thus, they limited the ARNP's involvement in central functions and direct management of the staff. The overall implementation of the demonstration project has benefited patients, staff, and the health care team. The continuity provided allows the patient and family to interact with a consistent person. The ARNP functions as the key to directing patient care in a holistic manner while facilitating staff development. The demonstration project has given the authors an opportunity to evaluate the management structure and redefine roles to achieve those outcomes in the management arena.
Collapse
Affiliation(s)
- C Counsell
- Shands Hospital, University of Florida, Gainesville, USA
| | | |
Collapse
|
34
|
Abstract
Physical restraints have been the standard of practice to manage certain types of patient behavior, such as unstable mobility, wandering, agitation, and interference with medical treatment. However, this intervention is not without serious negative consequences. Patients with neurological disorders or injuries are often at high risk for being restrained. The need to change to a more positive, patient-focused, restraint-free model was the goal of this project. A convenience sample of adult patients who were admitted to a neurological unit were studied. Outcome data that were assessed included (1) staff nurses' perception of restraints, (2) fall rate, (3) fall rate with injury, and (4) tube/line loss rate. Staff perceptions of restraints were assessed by administering the Perception of Restraints Use Questionnaire (PRUQ) before and after implementation of the restraint-reduced environment. The results of the outcome data support the change to a more restraint-reduced environment, as indicated by fall rate, fall rate with injury, and tube/line loss. Additionally, nurses' perceptions of restraints, as measured by the PRUQ, indicated a trend toward less emphasis on the use of restraints to control specific unsafe or undesirable patient behaviors.
Collapse
Affiliation(s)
- M Gilbert
- Shands Hospital, University of Florida, Gainesville, USA
| | | |
Collapse
|
35
|
|
36
|
Counsell C, Aaltonen H, Kilkku O, Heinonen E, Maki-Ikola O. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. BMJ 1998. [DOI: 10.1136/bmj.317.7172.1586] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
37
|
Counsell C. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required. BMJ 1998; 317:1586. [PMID: 9836669 PMCID: PMC1114394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
38
|
|
39
|
Abstract
Vagus nerve stimulation was recently approved for control of medically intractable seizures. This therapy provides some relief of seizures for selective patients, however seizure freedom using this device is uncommon. Vagus nerve stimulation appears to work by calming "hyperexcited" nerve cells and reverting brain activity to its normal patterns. Many people do have significant relief in the intensity and duration of their seizures and report improved quality of life using this device.
Collapse
Affiliation(s)
- C Snively
- Seizure Surgery Program, Shands Hospital, University of Florida, USA
| | | | | |
Collapse
|
40
|
Wardlaw JM, Lewis SC, Dennis MS, Counsell C, McDowall M. Is visible infarction on computed tomography associated with an adverse prognosis in acute ischemic stroke? Stroke 1998; 29:1315-9. [PMID: 9660379 DOI: 10.1161/01.str.29.7.1315] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE It is unclear whether visible infarction on a CT scan at any time after the stroke is an adverse prognostic factor once other factors such as stroke severity are taken into consideration. We examined whether visible infarction was associated with a poor outcome after stroke using univariate and multivariate analyses, including easily identifiable clinical baseline variables, and adjusting for time from stroke onset to CT. METHODS All inpatients and outpatients with an acute ischemic stroke attending our hospital stroke service were examined by a stroke physician and entered into a register prospectively. The CT scan was coded prospectively for the site and size of any relevant recent visible infarct. The patients were followed up at 6 months to ascertain their functional status with the use of the modified Rankin Scale. Analyses of the effect of visible infarction on the outcomes "dead or dependent" or "dead" at 6 months were performed with adjustment for time from stroke to CT, clinical stroke type (lacunar, hemispheric, or posterior circulation), and in a multiple logistic regression model to adjust for confounding baseline variables such as stroke severity. RESULTS In 993 patients in the stroke registry, visible infarction increased the risk of being dead or dependent at 6 months (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.9 to 3.3) or dead (OR, 4.5; 95% CI, 2.7 to 7.5), both on its own and after adjustment for time from stroke to CT, stroke symptoms, and other important clinical prognostic variables (OR for death or dependence in the predictive model, 1.5; 95% CI, 1.0 to 2.0; OR for death, 2.4; 95% CI, 1.4 to 4.1). CONCLUSIONS Visible infarction on CT is an adverse prognostic indicator (albeit of borderline significance) even after adjustment for stroke severity and time lapse between the stroke and the CT scan.
Collapse
Affiliation(s)
- J M Wardlaw
- Department of Clinical Neurosciences, Western General Hospital NHS Trust, Edinburgh, Scotland, UK.
| | | | | | | | | |
Collapse
|
41
|
Abstract
BACKGROUND AND PURPOSE Adequate outcome assessment is crucial to randomized trials. We wished to assess the types of outcomes used in acute stroke trials and the appropriateness of these outcomes and their analyses. METHODS Acute stroke trials from the Cochrane Stroke Group's database were included from 1955 to 1995 if they were published in full text in English. For each trial we collected year of publication, number of patients randomized, blinding of outcome assessment, the specific outcome instruments used, the statistical methods used for analysis, and the significance of the results. The validity and reliability of each outcome measure were assessed by review of the literature. RESULTS Our study included 174 trials. Outcomes were assessed blindly in 69%. Death was recorded in only 76% of trials, impairment in 76%, disability in 42%, and handicap or quality of life in only 2%. Of the trials that measured impairment, 35% used a measure of established validity or reliability. For disability and handicap, the proportions with valid or reliable measures were 70% and 25%, respectively. Impairment and handicap measures were primarily analyzed as continuous variables, while disability was mainly analyzed as a dichotomous variable. Continuous data were usually analyzed with inappropriate parametric statistics. There was no relationship between the method of analysis, the type of outcome, and the statistical significance of results. CONCLUSIONS Most acute stroke trials up to 1995 have used clinical outcome measures that were inadequate in terms of their content, reliability, validity, blinded assessment, and statistical analysis. This has important implications for future stroke research.
Collapse
Affiliation(s)
- L Roberts
- Department of Clinical Neurosciences, Western General Hospital, Edinburgh, Scotland
| | | |
Collapse
|
42
|
Counsell C, Naylor R, Warlow C. Regarding "Prospective randomized trials of carotid endarterectomy with primary closure and patch reconstruction: the problem is power". J Vasc Surg 1998; 27:386-7. [PMID: 9510299 DOI: 10.1016/s0741-5214(98)70377-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
43
|
Liu M, Counsell C, Wardlaw J, Sandercock P. A systematic review of randomized evidence for fibrinogen-depleting agents in acute ischemic stroke. J Stroke Cerebrovasc Dis 1998; 7:63-9. [PMID: 17895058 DOI: 10.1016/s1052-3057(98)80023-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/1997] [Accepted: 09/23/1997] [Indexed: 11/17/2022] Open
Abstract
OBJECTIVE To assess the efficacy and safety of fibrinogen-depleting agents (snake venom extracts) in the treatment of acute ischemic stroke. METHODS A systematic review of all the relevant randomized controlled trials (RCTs) was performed. RCTs were identified from the Cochrane Stroke Group's Specialized Trial Register, additional electronic and hand searching, and personal contact with pharmaceutical companies. We included all completed and unconfounded truly or quasi-randomized trials in patients with ischemic stroke comparing fibrinogen depleting agents with control started within 14 days of the stroke onset. The Peto method was used for analysis. RESULTS Eight completed and two ongoing RCTs have been identified so far. Only three trials using ancrod (182 patients) met the inclusion criteria. Ancrod was associated with a significant reduction in early deaths (5.6% v 16%; odds ratio [OR], 0.33; 95% confidence interval [CI], 0.13 to 0.85; 2P=.02) suggesting that treatment of 100 patients would avoid about 10 early deaths. The frequency of asymptomatic intracranial hemorrhage shown by computed tomography was similar between ancrod-treated and control groups (7.6% v 9.6%; OR, 0.78; 95% CI, 0.26 to 2.33; 2P=.65). No major intracranial or extracranial hemorrhages or recurrent ischemic strokes occurred in the ancrod-allocated patients. There were nonsignificant trends in favor of ancrod in death from any cause (OR, 0.57; 95% CI, 0.27 to 1.23; 2P=.15) and death or disability (OR, 0.52; 95% CI, 0.26 to 1.03; 2P=.06) at the end of trial follow-up. CONCLUSIONS There were too few patients and outcome events to draw reliable conclusions from the present data. Although ancrod-like agents appeared promising, their routine use cannot be recommended at the moment. Two ongoing trials (including about 1,000 patients in total) will provide more data. Future trials should test simpler fixed-dose regimens to allow better generalizability.
Collapse
Affiliation(s)
- M Liu
- Department of Clinical Neurosciences, University of Edinburgh, Scotland
| | | | | | | |
Collapse
|
44
|
Counsell C, Warlow C. Authors' reply. Eur J Vasc Endovasc Surg 1997. [DOI: 10.1016/s1078-5884(97)80300-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Counsell C, McDowall M, Dennis M. Hyperglycaemia after acute stroke. Other models find that hyperglycaemia is not independent predictor. BMJ 1997; 315:810; author reply 811. [PMID: 9345178 PMCID: PMC2127521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
46
|
Counsell C, McDowall M, Dennis M, Mitchell A, Kirckpatrick P, Scott J, O'Connell J, Gray C, Weir C, Dyker A, Lees K, Murray G. Hyperglycaemia after acute stroke. BMJ 1997. [DOI: 10.1136/bmj.315.7111.810] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
47
|
Abstract
Much time and effort are spent on designing primary research studies. Similar care must be given to planning systematic reviews. The review should be based on an important, well-focused question that is relevant to patient care. By formulating the question properly, the criteria that primary studies must meet to be included in the review become clear. These criteria, which comprise the types of persons involved, exposure, control group, outcomes, and study designs of interest, can then be refined so that they are clinically relevant, sensible, and workable. Inclusion criteria that are too narrow will limit the amount of data in the review, thereby increasing the risk for chance results and making the review less useful for the reader. Reviews should include studies whose designs offer the least biased answer to the question being asked. To maximize available data and reduce the risk for bias, as many relevant studies as possible need to be identified, regardless of publication status or language. Multiple overlapping search strategies should therefore be used and must be carefully planned. Strategies include searching the many electronic databases available (after careful consideration of which terms to enter), manually searching journals and conference proceedings, searching bibliographies of articles, searching existing registers of studies, and contacting companies or researchers. The time taken to formulate the question adequately and develop appropriate searches will increase the chance of producing a high-quality, meaningful review.
Collapse
Affiliation(s)
- C Counsell
- Department of Clinical Neurosciences, Western General Hospital, Edinburgh, United Kingdom
| |
Collapse
|
48
|
Abstract
BACKGROUND Recent trials of thrombolytic therapy in acute ischaemic stroke have given apparently conflicting results. Only one trial, the National Institute of Neurological Disorders and Stroke trial of tissue plasminogen activator (tPA), suggested that thrombolysis was definitely beneficial. To make sense of these results, we have done a systematic review of all available randomised trials of thrombolysis in acute ischaemic stroke. METHODS From all available completed randomised trials of thrombolytic therapy compared with control in acute ischaemic stroke (with prerandomisation CT), we checked tabular data on deaths during roughly the first 2 weeks, deaths from all causes and functional outcome (disability) at the end of the trial follow-up period, and early symptomatic and fatal intracranial haemorrhages. FINDINGS 12 trials included 3435 patients, of whom 694 (20%) were dead and 1001 (39%) of 2567 were functionally dependent at the end of follow-up (duration of follow-up varied between trials, but the longest was 6 months). 214 (6%) of the 3435 patients had early symptomatic or fatal intracranial haemorrhages. Thrombolytic therapy was associated with a significant excess of early deaths (91 per 1000 patients treated [95% CI 54-134]), and total deaths (37 per 1000 [20-83]), but there was nevertheless a significant reduction in the number of patients in the combined outcome of dead or dependent (65 fewer per 1000 patients treated [28-107]). There was a substantial and significant excess of symptomatic and fatal intracranial haemorrhages with thrombolysis-which was similar in all recent trials-of about 70 extra symptomatic intracranial haemorrhages per 1000 patients treated (of which 51 per 1000 were fatal). In the cohort of patients randomised within 3 h of stroke, there was a significant reduction in the number of patients who were dead or dependent at the end of follow-up (141 fewer dead or dependent per 1000 patients treated [75-206] and a non-significant increase in the number dead (nine per 1000 treated [-39 to 70]). There was significant heterogeneity between the trials for total deaths at the end of follow-up, which may be partly explained by differences in the use of antithrombotic drugs within the first 24 h of thrombolysis; the variation in severity of strokes included: the time window to thrombolytic treatment; and the dose of thrombolytic drug used. There were no direct comparisons of tPA with streptokinase or urokinase: much of the poor outcome in the streptokinase-treated patients might be explained by the inclusion of more severe strokes, greater use of antithrombotic drugs, higher doses, and the longer time to treatment compared with the trials that used tPA. INTERPRETATION Thrombolysis requires further testing in large randomised trials because the risks seem substantial, and the benefit uncertain. The time window for effective treatment remains unclear. There is no objective evidence to suggest that tPA is safer than streptokinase; the apparent hazards and benefits may be similar when differences in trial design and baseline variables are accounted for.
Collapse
Affiliation(s)
- J M Wardlaw
- Department of Clinical Neurosciences, University of Edinburgh, UK.
| | | | | |
Collapse
|
49
|
Ross L, Counsell C, Gilbert M. Maintaining the balancing act: restructuring at the unit level. J Nurs Adm 1996; 26:3-4. [PMID: 8968316 DOI: 10.1097/00005110-199612000-00001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- L Ross
- Shands Hospital, University of Florida, Gainesville, USA
| | | | | |
Collapse
|
50
|
Snively C, Counsell C, Gilbert M, Ross L. A coordinated care contest. J Nurs Staff Dev 1996; 12:264-5. [PMID: 8954405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|